Astellas Pharma Executive and Leadership Team

Atsushi Kitamura, the Chief Financial Officer at Astellas Pharma, directs all global financial operations and capital allocation strategies. Overseeing fiscal planning, the Chief Financial Officer ensures alignment with long-term pharmaceutical manufacturing goals. This leadership role involves managing investor relations and optimizing resource distribution across international markets. By maintaining rigorous financial controls, Atsushi Kitamura directly impacts the company's ability to fund critical research and development initiatives. Ultimately, Kitamura secures the financial stability necessary for sustained innovation in the competitive pharmaceutical landscape. The Chief Financial Officer also coordinates with the board to evaluate market risks and opportunities, ensuring that every investment supports the core mission of delivering life-changing therapies. Through precise fiscal oversight, Kitamura drives the economic health of the organization, enabling the pursuit of advanced medical breakthroughs while maintaining transparency and accountability for all stakeholders involved in the global enterprise.

Samuel Mantilha, the Country President and General Manager - South Cone Cluster and LATAM Partnership Markets at Astellas Pharma, directs regional operations and commercial growth across Latin American territories. Overseeing market expansion, the Country President and General Manager - South Cone Cluster and LATAM Partnership Markets ensures that pharmaceutical products reach patients in these critical emerging markets. This leadership role involves navigating complex regulatory environments and building strong local partnerships. By optimizing regional distribution networks, Samuel Mantilha directly impacts the company's footprint in the South Cone and beyond. Ultimately, Mantilha drives revenue and brand presence through localized strategic execution. The Country President and General Manager - South Cone Cluster and LATAM Partnership Markets also coordinates with global headquarters to ensure that regional activities align with the overarching corporate mission. Through effective leadership of local teams, Mantilha strengthens the company's position in the LATAM region, ensuring consistent delivery of healthcare solutions to diverse patient populations.

Ruibo Tang, the Senior Secretary To President at Astellas Pharma, directs the administrative flow and strategic communication for the office of the President. Overseeing executive scheduling and correspondence, the Senior Secretary To President ensures that the President remains focused on high-priority business objectives. This leadership role involves managing the flow of information between the executive office and other departments to facilitate efficient decision-making. By maintaining the operational rhythm of the leadership team, Ruibo Tang directly impacts the effectiveness of the company's governance. Ultimately, Tang supports the execution of the President's vision through meticulous coordination and administrative oversight. The Senior Secretary To President also coordinates with external stakeholders and board members to ensure seamless communication. Through the management of executive priorities, Tang drives the stability and focus of the leadership team, ensuring that the President can effectively guide the organization toward its long-term goals in the global pharmaceutical market.

Matthew Brieger, the Chief Marketing Officer & Manager, External Manufacturing Integration at Astellas Pharma, directs global brand positioning and supply chain synergy. Overseeing external manufacturing partnerships, the Chief Marketing Officer & Manager, External Manufacturing Integration ensures that production capabilities meet the rigorous demands of the pharmaceutical market. This leadership role involves bridging the gap between commercial strategy and manufacturing output to maximize product availability. By streamlining integration processes, Matthew Brieger directly impacts the efficiency of the global supply chain. Ultimately, Brieger optimizes market reach through strategic alignment of manufacturing assets and commercial objectives. The Chief Marketing Officer & Manager, External Manufacturing Integration also collaborates with regional teams to adapt marketing strategies for diverse healthcare environments. Through this dual focus on brand growth and operational integration, Brieger strengthens the market presence of the company, ensuring that essential medications reach patients with consistent quality and reliability across all international territories.

Dhanush Adiga, the Chief Marketing Officer, Lead Office (Reporting & Analytics) at Astellas Pharma, directs data-driven commercial strategies and performance analytics. Overseeing the reporting infrastructure, the Chief Marketing Officer, Lead Office (Reporting & Analytics) ensures that marketing decisions rely on precise, actionable insights. This leadership role involves interpreting complex market data to refine product positioning and enhance patient engagement. By leveraging advanced analytics, Dhanush Adiga directly impacts the effectiveness of commercial campaigns and resource allocation. Ultimately, Adiga drives revenue growth through the systematic application of data intelligence across the global portfolio. The Chief Marketing Officer, Lead Office (Reporting & Analytics) also coordinates with cross-functional teams to translate analytical findings into strategic business actions. Through the continuous monitoring of market trends and performance metrics, Adiga optimizes the commercial footprint of the company, ensuring that marketing efforts remain agile and responsive to the evolving needs of the global healthcare sector.

Tomohiro Kusawake, the Vice President, Chief of Staff for Research and Development, Head of CRDO Office at Astellas Pharma, directs the operational framework of the research and development division. Overseeing the CRDO office, the Vice President, Chief of Staff for Research and Development, Head of CRDO Office ensures that scientific innovation aligns with corporate strategic objectives. This leadership role involves managing the complex pipeline of pharmaceutical development and facilitating communication between research teams and executive leadership. By streamlining R&D processes, Tomohiro Kusawake directly impacts the speed and success of drug discovery efforts. Ultimately, Kusawake accelerates the delivery of new therapies to the market. The Vice President, Chief of Staff for Research and Development, Head of CRDO Office also coordinates with global scientific partners to foster collaborative breakthroughs. Through rigorous project management and strategic oversight, Kusawake drives the advancement of the company's medical portfolio, ensuring that research investments translate into tangible health outcomes for patients worldwide.

Sand'Eria Lewis, the Head of Strategic Collaboration Chief of Staff at Astellas Pharma, directs the formation and maintenance of high-impact external partnerships. Overseeing collaborative initiatives, the Head of Strategic Collaboration Chief of Staff ensures that alliances with academic institutions and biotech firms support the core research mission. This leadership role involves identifying synergy opportunities that expand the company's technological capabilities. By fostering these relationships, Sand'Eria Lewis directly impacts the innovation pipeline and market competitiveness. Ultimately, Lewis secures long-term growth through strategic networking and joint ventures. The Head of Strategic Collaboration Chief of Staff also coordinates with internal departments to integrate external expertise into existing development workflows. Through the cultivation of a robust partner ecosystem, Lewis drives the expansion of the company's scientific reach, ensuring that collaborative efforts remain aligned with the overarching goal of delivering advanced pharmaceutical solutions to patients across diverse global markets.

Katsuyoshi Sugita, the Chief People Officer at Astellas Pharma, directs global human capital strategy and organizational development. Overseeing talent acquisition and retention, the Chief People Officer ensures that the workforce possesses the skills necessary to drive pharmaceutical innovation. This leadership role involves fostering a culture of excellence and inclusivity across all international operations. By implementing robust professional development programs, Katsuyoshi Sugita directly impacts employee engagement and organizational performance. Ultimately, Sugita builds the leadership pipeline required for future success. The Chief People Officer also collaborates with executive leadership to align human resources initiatives with the broader business strategy. Through the continuous refinement of talent management practices, Sugita drives the growth of the company's internal capabilities, ensuring that the organization attracts and retains the top-tier talent needed to maintain a competitive edge in the global pharmaceutical industry while supporting the well-being of the entire workforce.

Samantha Yuen, the Chief People Officer, Enterprise Programs Lead, Office of & Director, Level) at Astellas Pharma, directs the execution of large-scale organizational programs and internal culture initiatives. Overseeing enterprise-wide projects, the Chief People Officer, Enterprise Programs Lead, Office of & Director, Level) ensures that human capital strategies support the company's operational goals. This leadership role involves designing and implementing programs that enhance organizational efficiency and employee alignment. By managing these complex initiatives, Samantha Yuen directly impacts the agility and effectiveness of the global workforce. Ultimately, Yuen drives cultural transformation and operational excellence. The Chief People Officer, Enterprise Programs Lead, Office of & Director, Level) also collaborates with other C-suite leaders to integrate people-focused strategies into the broader business framework. Through the systematic management of enterprise programs, Yuen fosters a high-performance environment, ensuring that the company remains well-positioned to meet the evolving challenges of the pharmaceutical sector while maintaining a focus on employee development.